en تخصصي Special پژوهشي Research <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span calibri="" style="font-family:"><b><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black">Objective:</span></span></span></b><b> </b><span style="font-size:10.5pt"><span new="" roman="" style="font-family:" times="">This study aimed to conduct a systematic review about diabetes mellitus and COVID-19 severity, management, and mortality.</span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span calibri="" style="font-family:"><b><span style="font-size:10.5pt"><span new="" roman="" style="font-family:" times="">Materials and Methods</span></span></b><b><span dir="RTL" lang="FA" style="font-size:10.5pt"><span new="" roman="" style="font-family:" times="">:</span></span></b> <span style="font-size:10.5pt"><span new="" roman="" style="font-family:" times="">Thirteen studies were included in this review, comprising a total of 1155 COVID-19 patients with diabetes mellitus as a significant comorbidity. Data regarding patient demographics and the prevalence of comorbidities, including smoking, hypertension, cardiovascular disease, chronic kidney disease, and chronic liver disease, were collected.</span></span></span></span></span></span><br> <span style="font-size:11pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span calibri="" style="font-family:"><b><span style="font-size:10.5pt"><span new="" roman="" style="font-family:" times="">Results</span></span></b><b><span dir="RTL" lang="FA" style="font-size:10.5pt"><span new="" roman="" style="font-family:" times="">:</span></span></b> <span style="font-size:10.5pt"><span new="" roman="" style="font-family:" times="">Among COVID-19 patients with diabetes mellitus, the majority were male (57.1%) compared to females (42.9%). The prevalence of comorbidities in COVID-19 are varied, with smokers accounting for 1-12.6%, hypertension ranging from 8-41.6%, diabetes mellitus ranging from 7.4-70.8%, cardiovascular disease ranging from 1.6-23.0%, chronic kidney disease ranging from 0.7-2.9%, and chronic liver disease ranging from 0.5-4.6%. In comparison to COVID-19 patients without diabetes, a higher proportion of patients with diabetes mellitus were admitted to the intensive care unit (36.8%). Among COVID-19 patients with diabetes mellitus, the survival rate was significantly higher at 62.2% compared to a lower rate of 13.4% observed among non-survivors with diabetes mellitus.</span></span></span></span></span></span><br> <b><span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">Conclusion</span></span></span><span dir="RTL" lang="FA" style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">:</span></span></span></b> <span style="font-size:10.5pt"><span style="line-height:115%"><span new="" roman="" style="font-family:" times="">This systematic review emphasizes the significance of diabetes mellitus as a comorbidity in COVID-19 patients, increasing the risk of ICU admission. These findings emphasize the importance of identifying and effectively managing diabetes mellitus as a comorbidity in COVID-19 patients to enhance overall outcomes.</span></span></span> COVID-19, Diabetes mellitus, Diabetes complications, SARS-CoV-2 181 189 http://ijdo.ssu.ac.ir/browse.php?a_code=A-10-30-388&slc_lang=en&sid=1 Seyed Hamid Akhlaghi 0000-0002-9595-8769 Yes KK College of Pharmacy, Gerugambakam, Chennai, India.